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Tuberculosis (TB) is the most important zoonotic bacterial disease in nonhuman primates (NHP). The
current diagnostic method, the intradermal palpebral tuberculin test, has serious shortcomings. We charac-
terized antibody responses in NHP against Mycobacterium tuberculosis to identify immunodominant antigens
and develop a rapid serodiagnostic test for TB. A total of 422 NHP were evaluated, including 243 rhesus
(Macaca mulatta), 46 cynomolgus (Macaca fascicularis), and 133 African green (Cercopithecus aethiops sabaeus)
monkeys at five collaborative centers. Of those, 50 monkeys of the three species were experimentally inoculated
withM. tuberculosis. Antibody responses were monitored every 2 to 4 weeks for up to 8 months postinfection by
MultiAntigen Print ImmunoAssay with a panel of 12 recombinant antigens. All of the infected monkeys
produced antibodies at various levels and with different antigen recognition patterns. ESAT-6 and MPB83 were
the most frequently recognized proteins during infection. A combination of selected antigens which detected
antibodies in all of the infected monkeys was designed to develop the PrimaTB STAT-PAK assay by lateral-flow
technology. Serological evaluation demonstrated high diagnostic sensitivity (90%) and specificity (99%). The
highest rate of TB detection was achieved when the skin test was combined with the PrimaTB STAT-PAK kit.
This novel immunoassay provides a simple, rapid, and accurate test for TB in NHP.
Tuberculosis (TB) remains one of the most important bac-
terial diseases of nonhuman primates (NHP) because of its
frequency of occurrence, ability to spread rapidly, high mor-
tality rates, and zoonotic potential (14, 26, 32). The disease in
NHP is caused by the same organisms that are responsible for
TB in humans (Mycobacterium tuberculosis) and cattle (Myco-
bacterium bovis) (4, 11, 33, 35). Infection can be readily trans-
mitted from one monkey to another or from monkeys to hu-
mans and vice versa (26, 31).
To control the spread of this devastating illness, captive
NHP are screened for TB regularly. The USDA-approved
method tests for delayed hypersensitivity in response to an
intradermal injection of mammalian old tuberculin (MOT)
into the skin of the eyelid (intrapalpebral tuberculin test) (8).
MOT is composed of poorly defined mycobacterial antigens
that are known to be highly cross-reactive (12, 25). The visual
scoring of the test is largely subjective, often allowing confu-
sion between negative and positive results (6, 15). In spite of
rigorous testing and import quarantine measures, outbreaks of
TB in NHP continue to occur in research laboratories, result-
ing in the destruction of numerous valuable animals in the
United States and elsewhere (14, 32). Many healthy primates
are also euthanized unnecessarily because of false-positive skin
test reactions that might be due to a nonspecific inflammatory
response to MOT or because of sensitization with cross-reac-
tive nonpathogenic species of environmental mycobacteria (10,
15, 17, 19). Thus, alternative diagnostic approaches for ante-
mortem TB testing of NHP are urgently needed.
We have recently developed two membrane-based antibody
detection methods, MultiAntigen Print ImmunoAssay (MAPIA)
and a lateral-flow test, and demonstrated the potential for rapid
TB serodiagnosis in various host species (16, 23, 34). In the
present study, we characterized the antibody responses in NHP
experimentally infected with M. tuberculosis and developed the
PrimaTB STAT-PAK assay, a novel lateral-flow test for antibody
detection in TB. This test was evaluated in comparison with the
intradermal palpebral tuberculin test and other laboratory diag-
nostic methods over the course of experimental infection.
MATERIALS AND METHODS
Animals and infection. A total of 422 NHP were used, including 243 rhesus
(Macaca mulatta), 46 cynomolgus (Macaca fascicularis), and 133 African green
(Cercopithecus aethiops sabaeus) monkeys from five collaborative centers (Table
1). At four research sites, experimental infection with M. tuberculosis was per-
formed on 50 animals, including 29 rhesus, 16 cynomolgus, and 5 African green
monkeys. Animal infection experiments were performed in biosafety level 3
facilities according to the study protocols approved by the Institutional Animal
Care and Use Committees. After prestudy quarantine and extensive evaluation
for TB, monkeys were inoculated intratracheally with various doses and strains of
M. tuberculosis (or M. avium or M. kansasii at the Tulane National Research
Primate Center [TNPRC]) as indicated in Table 1. Every 2 to 4 weeks after
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inoculation, the intrapalpebral MOT test was performed and at certain sites,
tracheal wash specimens were collected for culture and PCR-based testing (Am-
plified MTD; Gen-Probe, Inc., San Diego, CA). Serum samples were collected at
the same time for antibody detection methods. Durations of the experiments at
different sites varied from 7 weeks to 8 months, depending on the study design
and/or survival rates of infected monkeys. TB was confirmed by careful postmor-
tem examination including histopathology and acid-fast bacillus detection, as
well as culture and PCR probes. The control group combined 214 rhesus, 30
cynomolgus, and 128 African green monkeys. This group included six rhesus
macaques experimentally inoculated with two species of non-TB mycobacteria
(three with M. avium and three with M. kansasii), and the rest were uninoculated
monkeys.
Antigens. A panel of 12 defined proteins of M. tuberculosis (8 single recom-
binant proteins and 4 polyprotein fusions) was used in the MAPIA described
below. The following antigens were purified to near homogeneity as polyhisti-
dine-tagged proteins: ESAT-6 and CFP-10, produced at the Statens Serum
Institut (Copenhagen, Denmark); Mtb8 and Mtb48, kindly supplied by Raymond
Houghton of Corixa Corp. (Seattle, WA); MPB70 and MPB83, produced at the
Veterinary Sciences Division (Stormont, United Kingdom); and -crystallin
(Acr1) and the 38-kDa protein, purchased from Standard Diagnostics (Seoul,
South Korea). Hybrids CFP10/ESAT-6 and Acr1/MPB83 were constructed at the
Statens Serum Institut (Copenhagen, Denmark) by overlapping PCR with gene-
specific oligonucleotides to amplify the genes from M. tuberculosis H37Rv chro-
mosomal DNA. The fused polygene PCR products were cloned into the pMCT6
Escherichia coli expression vector with the SmaI/BamHI restriction enzymes.
Polyprotein fusions TBF10 and TBF6 were developed by Corixa Corp. and
purified as described earlier (18). Both constructs included Mtb8, CFP10, and
the 38-kDa protein; TBF6, additionally, had Mtb48 sequence. The M. bovis
culture filtrate used in the MAPIA was obtained from a field strain of M. bovis
(T/91/1378; Veterinary Sciences Division, Belfast, United Kingdom) cultured in
synthetic Sauton’s medium for 21 days.
MAPIA. The MAPIA immunoassay was performed as previously described
(21). Briefly, purified antigens were immobilized on nitrocellulose membrane
(Schleicher & Schuell, Keene, NH) at a protein concentration of 0.05 mg/ml with
a semiautomatic microaerosolization device (Linomat IV; Camag Scientific Inc.,
Wilmington, DE) to generate invisible parallel bands. After antigen printing, the
membrane was cut into strips 3.5 mm wide, perpendicular to the antigen bands,
so that each strip carried all of the antigens. Next, the strips were blocked for 1 h
with 1% nonfat skim milk in phosphate-buffered saline containing 0.05% Tween
20 and then incubated with individual serum samples diluted 1:50 in blocking
solution for 1 h at room temperature. After washing, the strips were incubated
for 1 h with peroxidase-conjugated protein G (Sigma) diluted 1:1,000 (Kirke-
gaard & Perry Laboratories), followed by another washing step. Immunoglobulin
G (IgG) antibodies bound to immobilized antigens were visualized with 3,3,5,5-
tetramethylbenzidine (Kirkegaard & Perry Laboratories). MAPIA results were
scored by two independent operators, with a band of any intensity being read as
a positive reaction.
PrimaTB STAT-PAK assay. The lateral-flow kit for rapid detection of anti-
bodies against M. tuberculosis and M bovis in NHP (Chembio Diagnostic Systems,
Inc., Medford, NY) uses a cocktail of recombinant antigens including ESAT-6,
CFP10, MPB83, and TBF10, as well as a blue latex bead-based signal detection
system. The ready-to-use disposable device consists of a plastic cassette contain-
ing a strip of nitrocellulose membrane impregnated with test antigen and lami-
nated with several pads made of glass fiber and cellulose. The test requires a
30-l serum sample (plasma or whole blood) and 3 drops of sample diluent
buffer (included in the kit) that are added sequentially to the sample pad. As the
diluted sample migrates to the conjugate pad, the latex particles conjugated to
the antigen bind the antibody, if present, thus creating a colored immune com-
plex. Driven by capillary forces, the complex flows laterally across the nitrocel-
lulose membrane and binds to the immobilized antigen, thus producing a visible
blue band in the test area of the device. In the absence of a specific antibody, no
band develops in the test window. The liquid continues to migrate along the
membrane, producing a similar blue band in the control area of the device,
irrespective of the presence of a specific antibody in the test sample, demon-
strating that the test reagents are functioning properly. Results are read visually
20 min after diluent addition. Any visible band in the test area, in addition to the
control line, is considered an antibody-positive result. The absence of a band in
the test area is considered an antibody-negative result. Figure 1 shows examples
of PrimaTB STAT-PAK assay results obtained with antibody-positive and -neg-
ative samples.
RESULTS
Antibody responses and antigen recognition. The humoral
immune response during experimental TB was characterized in
14 rhesus monkeys infected with M. tuberculosis at the TNPRC
and the University of South Alabama. To identify immuno-
dominant antigens, MAPIA was performed with serum sam-
ples sequentially collected at different time points during in-
FIG. 1. The PrimaTB STAT-PAK assay, a rapid lateral-flow test
for TB antibody detection in NHP. Shown are a negative result (on the
left) and a positive result (on the right); in the test window, the upper
line present in both devices is a control band; the lower line shown with
an arrow is the test band indicating a positive result.
TABLE 1. Study population
Research site and
monkey species Infection (no. of CFU)
No. of
monkeys
TNPRC
Rhesus M. tuberculosis Erdman (30) 5
Rhesus M. tuberculosis H37Rv (210) 4
Rhesus M. kansasii ATCC 12478 (260) 3
Rhesus M. avium ATCC 15769 (100) 3
Rhesus None 160
Cynomolgus M. tuberculosis Erdman (1,000) 7
Cynomolgus None 24
African green None 33
USAb
Rhesus M. tuberculosis Erdman (100) 5
Rhesus Nonea 5
MRL
Rhesus M. tuberculosis Erdman (100) 6
Cynomolgus M. tuberculosis Erdman (100) 6
African green M. tuberculosis Erdman (100) 5
BPRCc
Rhesus M. tuberculosis Erdman (1,000) 6
Rhesus M. tuberculosis Beijing (1,000) 3
Rhesus None 48
Cynomolgus M. tuberculosis Erdman (1,000) 3
Cynomolgus None 6
BSFLd
African green None 95
a Preinoculation serum samples were used as a negative control group.
b USA, University of South Alabama.
c BPRC, Biomedical Primate Research Centre.
d BSFL, Behavioral Sciences Foundation Laboratories.
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fection. Examples of MAPIA strips obtained with serial
specimens collected from two of the infected monkeys repre-
senting different antigen reactivity patterns are shown in Fig. 2.
The overall results of the antigen recognition study are sum-
marized in Table 2.
The infected animals started producing antibodies at various
time points postinoculation. Specific IgG responses could be
detected as early as 4 weeks after a challenge with M. tubercu-
losis. The postinfection serum samples from different monkeys
showed various recognition patterns reacting with one or more
antigens in the MAPIA (Fig. 2). Seven of eight single recom-
binant proteins and all four polyprotein fusions were reactive
with samples from at least one monkey. None of the antigens
was positive with preinfection serum samples. The most fre-
quently recognized proteins were ESAT-6 and MPB83, fol-
lowed by CFP10, Acr1, MPB70, Mtb8, and the 38-kDa protein
of M. tuberculosis (Table 2). The polyproteins had particularly
strong reactivity with serum samples that recognized single
antigens which were part of the respective fusions (Fig. 2).
Analysis of ESAT-6 and MPB83 seroreactivities. Antibody
responses against the two most dominant antigens were further
characterized (Table 3). We tested serial serum samples from
infected monkeys by MAPIA in three independent experi-
ments (two at the TNPRC and one at the University of South
Alabama) to compare antigen recognition patterns, the mag-
nitudes of the antibody responses, and the times from inocu-
lation of M. tuberculosis to onset of seroconversion found with
these antigens because detection of earlier and stronger anti-
body responses may provide a more robust TB test. We found
that in each experiment the infected monkeys produced a
spectrum of antibody responses of various magnitudes and
antigen recognition profiles. There appeared to be no differ-
ence between the animal groups infected with different doses
(30, 100, or 210 CFU) or strains of M. tuberculosis (Erdman or
H37Rv). Interestingly, while the total numbers of antibody
reactors to ESAT-6 and MPB83 were identical (10/14), the
proportions of earlier antibody responders to each of the an-
tigens were significantly different (seven for MPB83 versus
three for ESAT-6 and three for both antigens simultaneously).
One animal (no. 653) recognized neither of the two antigens
but had antibody against CFP10.
Although each of the two immunodominant proteins,
ESAT-6 and MPB83, was reactive in 71% of the infected
monkeys, a combination of the two antigens in the MAPIA
detected 93% (13/14) of this group. By week 12 postinocula-
tion, antibody against at least one recombinant antigen in the
panel was present in 100% of the infected monkeys, thus sug-
gesting that a multiantigen cocktail would provide optimal
serodiagnostic sensitivity.
FIG. 2. Serum IgG antibody responses in rhesus macaques exper-
imentally infected with M. tuberculosis. MAPIA was performed as
described in Materials and Methods. Panels: A, monkey no. 304; B,
monkey no. 595. Each panel of strips shows results obtained with a set
of serum samples serially collected over time from an experimentally
infected monkey. Each strip represents one serum sample collected at
the time point indicated. Bands on MAPIA strips show the presence of
antibodies to antigens printed onto the membrane (listed on the right).
TABLE 2. Antigen recognition by serum antibodies in 14 rhesus
macaques infected with M. tuberculosis at the TNPRC and
the University of South Alabama
Antigen No. (%) of antibody reactors
Single proteins
ESAT-6 .........................................................................10 (71)
MPB83 ..........................................................................10 (71)
CFP10............................................................................ 7 (50)
Acr1 ............................................................................... 6 (43)
MPB70 .......................................................................... 5 (36)
Mtb8 .............................................................................. 2 (14)
38 kDa........................................................................... 1 (7)
Mtb48 ............................................................................ 0 (0)
Polyprotein fusions
CFP10/ESAT-6.............................................................11 (79)
Acr1/MPB83.................................................................12 (86)
TBF10 ........................................................................... 9 (64)
TBF6 ............................................................................. 9 (64)
TABLE 3. Animal-to-animal variation of antibody recognition of
the two immunodominant antigens during experimental TB in
rhesus macaques evaluated at the TNPRC and the
University of South Alabama
M. tuberculosis strain (dose CFU)
and animal identification no.
Antibody responsea
ESAT-6 MPB83
Erdman (30)
209  
283  
304  
653  
814  
Erdman (100)
847  
855  
861  
867  
056  
H37Rv (210)
590  
595  
727  
729  
a The results for antigens eliciting the earliest antibody in each infected animal
are in bold. The magnitude of the antibody response was visually scored for each
antigen as very strong (), strong (), weak (), or nonreactive ().
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Development and evaluation of the PrimaTB STAT-PAK
assay. On the basis of the antigen screening results, we se-
lected ESAT-6, CFP10, MPB83, and TBF10 for inclusion in
the antigen cocktail to develop a lateral-flow test. These anti-
gens, when combined, were sufficient to cover animal-to-ani-
mal variation in antibody reactivity patterns. The ESAT-6 and
CFP10 proteins were incorporated as a CFP10/ESAT-6 hybrid
molecule which displayed superior antigen reactivity over the
single proteins (an example is shown in Fig. 2A). Several key
lateral-flow assay conditions (antigen coating concentration,
membrane type, sample diluent composition, and conjugate
type) were optimized to provide the best discrimination be-
tween TB and control serum samples.
The PrimaTB STAT-PAK assay developed was then evalu-
ated with serum samples from the experimentally infected rhe-
sus macaques used for the MAPIA-based antigen screening
work, as well as with additional specimens derived from other
experimental infection studies performed with rhesus, cyno-
molgus, and African green monkeys. Extended control groups
of the same species were also included.
We found that the serological performance of the PrimaTB
STAT-PAK assay was in agreement with the MAPIA data
obtained with the same set of serum samples. The rapid test
was able to detect serum antibody in all three host species
starting at 4 to 8 weeks postinfection with relatively high diag-
nostic accuracy. The overall sensitivity of the PrimaTB STAT-
PAK assay in this evaluation was 90.0%, and the specificity was
98.9% (Table 4). On the basis of these results, the positive
predictive value was 91.8% and the negative predictive value
was 98.7%. When the specificity of the PrimaTB STAT-PAK
assay was challenged in one of the TNPRC experiments with
rhesus macaques inoculated twice with M. avium or M. kansa-
sii, no serological cross-reactivity was found in the six monkeys
used in the study.
How the PrimaTB STAT-PAK assay compares with other
antemortem tests. The intrapalpebral tuberculin test was re-
peatedly performed during experimental TB in two of the
studies reported here, one at the University of South Alabama
with five rhesus macaques and the other at Merck Research
Laboratories (MRL) with 17 NHP including groups of rhesus,
cynomolgus, and African green monkeys. The antibody re-
sponses could therefore be compared with the skin test results
obtained with these animals at the same time points during
infection.
In the University of South Alabama study, positive skin test
results were documented at week 6 in two of five infected
monkeys and at week 8 in one of five infected monkeys; none
was reactive at week 4 or between weeks 8 and 14 (end of
study). The PrimaTB STAT-PAK assay started showing posi-
tive results by weeks 6 and 8 of infection (one of five and two
of five, respectively), followed by consistent antibody detection
in four of five infected monkeys in the following 6 weeks.
In the MRL experiment, the PrimaTB STAT-PAK assay was
compared with the intrapalpebral tuberculin test, bacterial cul-
ture, and PCR-based probes with tracheal wash samples over
the course of infection (Table 5). We found that while the skin
test was most sensitive (88%) at 4 weeks postinoculation, its
diagnostic value declined drastically in the following 4 to 8
weeks and no MOT reactors were detected after 2 months
postinoculation until the end of the experiment (up to 8
months). In contrast, the PrimaTB STAT-PAK assay turned
increasingly positive between weeks 4 and 8 postinoculation,
consistently detecting 100% of the infected monkeys thereaf-
ter. Tracheal wash culture and PCR testing showed variable
performance with intermittent positive and negative results
obtained with the same animals. If the skin test and the
PrimaTB STAT-PAK assay are combined, such a testing algo-
rithm holds promise to be the most sensitive diagnostic ap-
proach for the early and reliable detection of TB in NHP
(Table 5).
DISCUSSION
TB control programs in NHP research colonies require ur-
gent improvements of testing methods. The only USDA-ap-
proved technology, the intradermal palpebral tuberculin test,
has serious limitations. Both false-negative and false-positive
reactions are common, often resulting in spread of infection
and devastating TB outbreaks or leading to unjustified eutha-
nasia of valuable noninfected animals (15, 32). To further
complicate early diagnosis, symptoms suggestive of TB in NHP
are not always obvious to help recognize disease. In a recent
TB outbreak due to M. bovis in a conditioned colony, clinical
signs were observed in 5 of 8 infected rhesus macaques and
TABLE 4. Diagnostic performance of the PrimaTB STAT-PAK
assay evaluated at the five research sites
Monkey species % Sensitivity(no. positive/total)
% Specificity
(no. positive/total)
Rhesus 89.7 (26/29) 98.6 (216/219)
Cynomolgus 93.8 (15/16) 100.0 (30/30)
African green 80.0 (4/5) 99.2 (127/128)
All 90.0 (45/50) 98.9 (373/377)
TABLE 5. Numbers of positive results obtained by different methods over the course of experimental infection with
M. tuberculosis in NHP performed at MRL
Method
No. positive/total (%) at postinoculation wk:
0 4 8 12 16 20 24
Skin testa 0/17 (0) 15/17 (88) 7/17 (41) 0/6 (0) 0/6 (0) 0/6 (0) 0/6 (0)
PrimaTB STAT-PAK 0/17 (0) 3/17 (18) 10/15 (67) 11/11 (100) 10/10 (100) 10/10 (100) 8/8 (100)
Tracheal wash culture 0/17 (0) 7/17 (41) 8/17 (47) 9/12 (75) 5/7 (71) 6/10 (60) 5/8 (63)
Tracheal wash PCR 0/17 (0) 4/17 (24) 5/17 (29) 2/12 (17) 1/9 (11) 5/10 (50) 4/8 (50)
Skin test  PrimaTB STAT-PAK 0/17 (0) 16/17 (94) 14/17 (82) 11/11 (100) 10/10 (100) 10/10 (100) 8/8 (100)
a Starting at 12 weeks postinoculation, the skin test was performed only on the group of six infected cynomolgus monkeys.
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only 1 of 19 infected cynomolgus macaques (14). In the latter
group, the intrapalpebral MOT test failed to identify three
infected monkeys, suggesting that additional diagnostic meth-
ods must be implemented to improve TB screening programs.
Blood-based immunoassays constitute a promising alterna-
tive for TB detection (1, 23). Tuberculin-induced lymphocyte
transformation methods showed promise in early studies (2, 5,
27), but this approach has never resulted in the development of
a diagnostic test. Recent studies evaluated the whole-blood in
vitro gamma interferon assay (Primagam; Prionics, Schlieren-
Zurich, Switzerland) in experimental and natural infections
(13, 32). Although encouraging results were presented in com-
parison with the tuberculin skin test, the authors revealed
interspecies differences and recommended a certain optimiza-
tion of the Primagam interpretation cutoff values, particularly
for cynomolgus macaques (13). This laboratory immunoassay
requires dedicated equipment and technical expertise.
Antibody detection methods are simple, rapid, accurate, and
relatively inexpensive. Attempts have been made to develop a
serodiagnostic TB test for NHP by using various antigens and
techniques (3, 7, 9, 20, 24). Lateral-flow technology offers im-
portant features that make it a most attractive and user-
friendly immunoassay format, especially for animal-side appli-
cations. Although numerous attempts to develop a rapid
serodiagnostic test for human TB have been disappointing (28,
29, 30), the potential of this approach for TB detection in
animals has been recently demonstrated (16, 23). In the
present report, we describe the development and evaluation of
the PrimaTB STAT-PAK assay, a novel, rapid lateral-flow
device for the detection of antibodies to M. tuberculosis in
NHP. The test uses a unique cocktail of selected M. tubercu-
losis recombinant antigens. The PrimaTB STAT-PAK assay is
an easy-to-perform all-inclusive disposable kit which can use
serum, plasma, or fresh whole-blood samples to provide yes-
or-no results within 15 to 20 min. The test is stable at room
temperature for up to 12 months, and it does not require
refrigeration for storage, electricity, equipment, laboratory set-
ting, or skilled personnel. In addition to the visual reading
option, an optical reader can be used (23), if desired, for
printable numerical readouts, as well as data documentation
and storage. This novel immunodiagnostic method is an im-
provement over the current tuberculin test in that it can pro-
duce almost instant results instead of the currently required
72 h of repeated observations.
To develop the PrimaTB STAT-PAK assay, we first charac-
terized the antibody responses of rhesus macaques with exper-
imental TB. The primary goal was to identify the seroreactive
antigens by MAPIA with serum samples serially collected from
monkeys inoculated with M. tuberculosis. The present study has
confirmed that ESAT-6 is among the most prominent proteins
of M. tuberculosis recognized by antibodies during TB in NHP
(3). We have also found that the CFP10/ESAT-6 hybrid used
in the membrane-based immunoassays is a more sensitive re-
agent for the detection of anti-ESAT-6 antibody than the sin-
gle ESAT-6 protein. Further, we identified another prominent
B-cell antigen, MPB83, which showed a rate of seroreactivity
(71%) equal to that of ESAT-6 but stronger recognition at
earlier stages of infection. These two proteins were combined
with CFP10 and TBF10 for the development of the PrimaTB
STAT-PAK assay. Importantly, the selected antigens are
known to be specific for the M. tuberculosis complex, thus
providing the necessary basis for a highly accurate TB serodi-
agnostic test (1).
Evaluation of the PrimaTB STAT-PAK assay with well-char-
acterized serum samples from 50 infected and 377 control
NHP including rhesus, cynomolgus, and African green mon-
keys showed that the test could detect serum antibody in all
three species. The PrimaTB STAT-PAK assay demonstrated
high positive and negative predictive values, correctly identi-
fying 90% of the animals in the infected group and 99% of the
animals in the control group. Importantly, the test did not have
any cross-reactivity with serum samples from monkeys inocu-
lated with M. avium or M. kansasii, the species known to be
involved in non-TB mycobacterioses in NHP that can produce
false-positive tuberculin skin test reactions (15, 17, 19).
The MRL study revealed noticeable differences among the
three NHP species in susceptibility to experimental TB and
the clinical course of the disease. African green monkeys were
exquisitely sensitive to M. tuberculosis inoculation, with all five
animals in the group euthanized within 2 months of infection
because of persistent clinical signs such as coughing, anorexia,
and/or weight loss. They displayed intermittent-to-chronic
coughing from about 4 weeks postinoculation until termina-
tion. Rhesus monkeys had a variable course of disease, with
four animals euthanized between 2 and 6 months postinfection
and two animals euthanized at 7.5 months (study termination).
They all coughed from 1 to 5 months postinoculation. Cyno-
molgus monkeys displayed a more chronic infection, with two
animals euthanized at 5.5 and 7 months, respectively, and the
other four at study termination. In this group, three of the six
cynomolgus monkeys coughed between 3 and 6 months posti-
noculation. On necropsy, all of the animals had gross evidence
of TB and M. tuberculosis was isolated via culture and PCR
assay of various tissues. Pathology was generally related to the
length of time the disease progressed, with all of the animals
displaying various degrees of severity of generalized dissemi-
nated TB. Acute, multifocal necrosis was seen in tissues from
the vervets, granulomas with multinucleate giant cells were
present in rhesus monkey tissues, and caseous granulomas
with mature fibrous connective tissue capsules were appar-
ent in the cynomolgus monkeys. Importantly, the PrimaTB
STAT-PAK assay could detect specific antibody in all of the
infected monkeys, irrespective of the host species, the clin-
ical course of the disease, the extent of pathology, and the
results of other diagnostic tests.
One common limitation of the serodiagnostic methods com-
pared to the cell-mediated immune response assays, such as
the intradermal test or Primagam, is that antibody responses in
TB typically develop at later stages of infection (1, 22). In this
study, we have demonstrated, however, that certain antigens,
such as MPB83, can elicit antibodies much earlier than others
and that the PrimaTB STAT-PAK assay can detect infected
monkeys as early as week 4 of infection. Furthermore, the
diagnostic window may be reduced by the use of more than one
assay. Since the PrimaTB STAT-PAK assay could detect anti-
body in the infected monkeys with advanced disease which
became consistently negative by the tuberculin skin test (aner-
gic), we suggest that a combined application of the two tests
will likely provide the best testing algorithm for earlier and
more reliable detection of TB in NHP. Our recent observa-
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tions in several TB outbreaks where the PrimaTB STAT-PAK
assay was compared with the tuberculin test and Primagam
support this view (K. P. Lyashchenko, unpublished data).
The present report does not address two important ques-
tions, i.e., (i) whether the experimental infection models used
for test development and evaluation adequately reflect natu-
rally occurring disease and (ii) whether the PrimaTB STAT-
PAK assay can detect TB caused by M. bovis. Preliminary
evidence suggests that the PrimaTB STAT-PAK assay can
work equally well in natural infections with M. tuberculosis and
M. bovis (Lyashchenko et al., unpublished). Additional work is
in progress to extend this application to other primate species.
Also, the NHP models of latent TB and active disease (11) may
offer a useful approach for the further characterization of
serological responses in human patients and the development
of more accurate TB assays where certain immunological
aspects cannot be addressed otherwise.
In summary, the present report described the antibody re-
sponses against multiple recombinant proteins of M. tubercu-
losis over the course of experimental infection in rhesus mon-
keys. We identified and characterized previously unknown
immunodominant antigens and potent fusion polyproteins. A
unique cocktail of selected TB-specific antigens was incorpo-
rated in the optimized lateral-flow format to develop the
PrimaTB STAT-PAK assay. Serologic evaluation of this novel
diagnostic tool used alone or in conjunction with the intrader-
mal tuberculin test demonstrated the potential for improved
sensitivity of TB screening programs in NHP research colonies.
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